Clinical Trials
4
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:3
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 2
1 (25.0%)A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.
Phase 2
Completed
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Kevin Flanigan
- Target Recruit Count
- 3
- Registration Number
- NCT04179409
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
Spironolactone Versus Prednisolone in DMD
Phase 1
Terminated
- Conditions
- Muscular Dystrophy, Duchenne
- Interventions
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Kevin Flanigan
- Target Recruit Count
- 2
- Registration Number
- NCT03777319
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Gene Transfer Clinical Trial to Deliver rAAVrh74.MCK.GALGT2 for Duchenne Muscular Dystrophy
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Kevin Flanigan
- Target Recruit Count
- 2
- Registration Number
- NCT03333590
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2
Phase 1
Withdrawn
- Conditions
- Duchenne Muscular Dystrophy
- First Posted Date
- 2016-03-10
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Kevin Flanigan
- Registration Number
- NCT02704325
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
News
No news found